Patient characteristics
| . | All patients∗ . | WHO-AML-MR . | ICC-AML-MR-M/CG . | P values† . |
|---|---|---|---|---|
| Patients | 432 | 354 | 276 | |
| Sex, male/female | 273/159 | 234/120 | 194/82 | .264 |
| Median age (range), y | 72 (18, 95) | 72 (19, 95) | 72 (18, 95) | .224 |
| BM Blast‡ (%) | 40 (12, 97) | 38 (12, 96) | 40 (12, 97) | .292 |
| WBC count (×109/L) | 3.7 (0.1, 328.7) | 3.7 (0.1, 328.7) | 4.4 (0.1, 328.7) | .131 |
| Hemoglobin (g/L) | 85 (11, 197) | 86 (11, 169) | 86 (11, 169) | .680 |
| Platelet (×109/L) | 56 (5, 2,726) | 56.5 (6, 2,726) | 61 (6, 2,726) | .344 |
| LDH (U/L) | 307 (90, 9,473) | 309 (90, 9,473) | 279 (90, 9,473) | .538 |
| Prior MDS or MDS/MPN | 48 (11%) | 50 (14%) | 45 (16%) | .488 |
| Prior cytotoxic therapy | 28 (6.5%) | 0 (0%) | 12 (4.4%) | <.001∗∗ |
| Cytogenetics | ||||
| Abnormal karyotype | 308 (71%) | 264 (75%) | 180 (65%) | .011∗∗ |
| CK | 176 (41%) | 159 (45%) | 68 (25%) | <.001∗∗ |
| +8 | 73 (17%) | 63 (18%) | 53 (19%) | .660 |
| −17 | 63 (15%) | 53 (15%) | 7 (3%) | <.001∗∗ |
| Gene mutations | ||||
| Median mutations (range) | 3 (0, 9) | 3 (0, 9) | 4 (0, 9) | .012∗∗ |
| FLT3-ITD§ | 29 (20%) | 23 (22%) | 25 (29%) | .518 |
| TP53 | 115 (27%) | 100 (28%) | 0 (0%) | <.001∗∗ |
| RUNX1 | 107 (25%) | 95 (27%) | 104 (38%) | .004∗∗ |
| ASXL1 | 97 (23%) | 94 (27%) | 93 (33%) | .051 |
| DNMT3A | 83 (19%) | 66 (19%) | 53 (19%) | .859 |
| IDH2 | 64 (16%) | 55 (16%) | 55 (20%) | .169 |
| IDH1 | 45 (10%) | 37 (10%) | 29 (11%) | .982 |
| NRAS | 37 (8.6%) | 28 (8%) | 31 (11%) | .156 |
| CEBPA‖ | 27 (6.2%) | 25 (7%) | 25 (9%) | .358 |
| KRAS | 22 (5.1%) | 17 (5%) | 18 (6%) | .350 |
| ELN 2022 subgroups | .289 | |||
| Adverse | 377 (87%) | 345 (97%) | 263 (95%) | |
| Intermediate | 54 (13%) | 8 (2%) | 12 (4%) | |
| Therapies and outcomes | ||||
| Intensive chemotherapy | 215 (50%) | 172 (50%) | 148 (55%) | .606 |
| Low-intensity therapies | 93 (21%) | 83 (24%) | 59 (22%) | |
| HMA/venetoclax | 43 (10%) | 41 (12%) | 35 (13%) | |
| Best supportive care | 81 (19%) | 48 (14%) | 27 (10%) | |
| CR§,¶ | 143 (69%) | 108 (66%) | 101 (73%) | .230 |
| Relapse§,¶ | 76 (60%) | 55 (60%) | 48 (55%) | .533 |
| HCT | 115 (27%) | 88 (25%) | 84 (31%) | .119 |
| . | All patients∗ . | WHO-AML-MR . | ICC-AML-MR-M/CG . | P values† . |
|---|---|---|---|---|
| Patients | 432 | 354 | 276 | |
| Sex, male/female | 273/159 | 234/120 | 194/82 | .264 |
| Median age (range), y | 72 (18, 95) | 72 (19, 95) | 72 (18, 95) | .224 |
| BM Blast‡ (%) | 40 (12, 97) | 38 (12, 96) | 40 (12, 97) | .292 |
| WBC count (×109/L) | 3.7 (0.1, 328.7) | 3.7 (0.1, 328.7) | 4.4 (0.1, 328.7) | .131 |
| Hemoglobin (g/L) | 85 (11, 197) | 86 (11, 169) | 86 (11, 169) | .680 |
| Platelet (×109/L) | 56 (5, 2,726) | 56.5 (6, 2,726) | 61 (6, 2,726) | .344 |
| LDH (U/L) | 307 (90, 9,473) | 309 (90, 9,473) | 279 (90, 9,473) | .538 |
| Prior MDS or MDS/MPN | 48 (11%) | 50 (14%) | 45 (16%) | .488 |
| Prior cytotoxic therapy | 28 (6.5%) | 0 (0%) | 12 (4.4%) | <.001∗∗ |
| Cytogenetics | ||||
| Abnormal karyotype | 308 (71%) | 264 (75%) | 180 (65%) | .011∗∗ |
| CK | 176 (41%) | 159 (45%) | 68 (25%) | <.001∗∗ |
| +8 | 73 (17%) | 63 (18%) | 53 (19%) | .660 |
| −17 | 63 (15%) | 53 (15%) | 7 (3%) | <.001∗∗ |
| Gene mutations | ||||
| Median mutations (range) | 3 (0, 9) | 3 (0, 9) | 4 (0, 9) | .012∗∗ |
| FLT3-ITD§ | 29 (20%) | 23 (22%) | 25 (29%) | .518 |
| TP53 | 115 (27%) | 100 (28%) | 0 (0%) | <.001∗∗ |
| RUNX1 | 107 (25%) | 95 (27%) | 104 (38%) | .004∗∗ |
| ASXL1 | 97 (23%) | 94 (27%) | 93 (33%) | .051 |
| DNMT3A | 83 (19%) | 66 (19%) | 53 (19%) | .859 |
| IDH2 | 64 (16%) | 55 (16%) | 55 (20%) | .169 |
| IDH1 | 45 (10%) | 37 (10%) | 29 (11%) | .982 |
| NRAS | 37 (8.6%) | 28 (8%) | 31 (11%) | .156 |
| CEBPA‖ | 27 (6.2%) | 25 (7%) | 25 (9%) | .358 |
| KRAS | 22 (5.1%) | 17 (5%) | 18 (6%) | .350 |
| ELN 2022 subgroups | .289 | |||
| Adverse | 377 (87%) | 345 (97%) | 263 (95%) | |
| Intermediate | 54 (13%) | 8 (2%) | 12 (4%) | |
| Therapies and outcomes | ||||
| Intensive chemotherapy | 215 (50%) | 172 (50%) | 148 (55%) | .606 |
| Low-intensity therapies | 93 (21%) | 83 (24%) | 59 (22%) | |
| HMA/venetoclax | 43 (10%) | 41 (12%) | 35 (13%) | |
| Best supportive care | 81 (19%) | 48 (14%) | 27 (10%) | |
| CR§,¶ | 143 (69%) | 108 (66%) | 101 (73%) | .230 |
| Relapse§,¶ | 76 (60%) | 55 (60%) | 48 (55%) | .533 |
| HCT | 115 (27%) | 88 (25%) | 84 (31%) | .119 |
BM, bone marrow; WBC, white blood cell; LDH, lactate dehydrogenase; MDS, myelodysplastic syndromes; MDS/MPN, myelodysplastic/myeloproliferative neoplasms; CK, complex karyotype; ELN, European LeukemiaNet; HCT, hematopoietic cell transplantation; CR, complete remission; OS, overall survival.
Median (range) or frequency (%).
Pearson χ2test; Wilcoxon rank sum test; Fisher exact test; comparisons were between WHO-AML-MR and ICC-AML-MR-M/CG.
Two patients with 12% bone marrow blasts had >20% blasts in peripheral blood.
FLT3-ITD: available in 148 patients, 284 were missing; CR: available in 208 patients; Relapse: available in 127 patients.
CEBPA mutations other than those which meet the criteria from either WHO or ICC for defining AML with mutated CEBPA.
CR and Relapse were calculated for those who treated by intensive chemotherapy.
Statistically significant P values.